Loading the Newsroom

AstraZeneca is understood to be in talks to buy Bristol Myers Squibb, reshaping deal math and regulatory scrutiny at scale.

A failed late-stage heart study triggered a swift market punishment, forcing investors and boards to reset timelines and risk.